Recent developments in the world’s leading generic markets

Medicinski Casopis

Volumn 48, Issue 3, 2014, Pages 140-142

  Jakovljevic, Mihajlo B ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Drugs; Economics; Generic; Marketing; Medical

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; GENERIC DRUG; NEUROLEPTIC AGENT;

ARTICLE; CONSUMER; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HUMAN; PRESCRIPTION;

EID: 84943607983     PISSN: 03501221     EISSN: 24060380     Source Type: Journal    
DOI: 10.5937/mckg48-5071     Document Type: Article

References (16)

1. Shepard a. Generic medicines: essential contributors to the long-term health of society. Sector sustainability challenges in Europe. Danbury: imS health, 2010. (http://www.imshealth.com/imshealth/Global/ Content/imS%20institute/Documents/Generics_ medicines.pdf)
2. Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. health aff (millwood) 2006; 25: 1353-62.
3. Decollogny a, Eggli Y, halfon P, Lufkin tm. Determinants of generic drug substitution in Switzerland. BmC health Serv res 2011; 11: 17.
4. Yamada T, Chen CC, Yamada T, Chiu Im, Worrall J. pharmaceutical price control policy, pharmaceutical innovation, and health durability. toPharmEJ 2010; 2: 34-46.
5. Sachiko M. the market exclusivity period for new drugs in Japan: overview of intellectual property protection and related regulations. Journal of Generic medicines 2008; 5: 121-130.
6. Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. authorized generic drugs, price competition, and consumers' welfare. health aff (millwood) 2007; 26: 790-9.
7. Frank RG. the ongoing regulation of generic drugs. n Engl J med 2007; 357: 1993-6.
8. Peters JR, Hixon DR, Conner DP, Davit BM, Catterson DM, Parise Cm. Generic drugs-safe, effective, and affordable. Dermatol ther 2009; 22: 229-40.
9. Kuehn Bm. mr Waxman went to Washington: congressman an architect of health laws for 4 decades. Jama 2014; 311: 1386-8.
10. Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert rev Pharmacoecon outcomes res 2014; 14: 181-94.
11. Babar ZU, Grover P, Stewart J, et al. Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in new Zealand. res Social adm Pharm 2011; 7: 294-305.
12. Lofgren H. Generic drugs: international trends and policy developments in australia. aust health rev 2004; 27: 39-48.
13. Searles A, Jefferys S, Doran E, Henry DA. reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. med J aust 2007; 187: 236-9.
14. Liu YM, Yang YH, Hsieh CR. Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: evidence from taiwan. J health Econ 2009; 28: 341-9.
15. Shukla N, Sangal T. Generic drug industry in india: the counterfeit spin. Journal of intellectual Property rights 2009; 14: 236-240.
16. Sun Q, Santoro MA, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. health aff (millwood) 2008; 27: 1042-50.